Erythropoietic Protoporphyria clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
open to eligible people ages 18 years and up
This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.
Our lead scientists for Erythropoietic Protoporphyria research studies include Bruce Wang, MD.